Table 8.

Summary of treatment discontinuation/change and adverse events for pyrimethamine plus sulfadiazine and pyrimethamine plus sulfadoxine

Manifestation	Discontinued/change in treatment	Bone marrow suppression	Gastrointestinal	Dermatologic
Pyrimethamine plus sulfadiazine
Frequency by study	14/19 (73.7%)	11/19 (57.9%)	6/19 (31.6%)	8/19 (42.1%)
Prevalence, range	1.8–50.0%	2.8–45.8%	1.8–100%	1.5–11.0%
Pyrimethamine plus sulfadoxine
Frequency by study	5/6 (83.3%)	5/6 (83.3%)	3/6 (50.0%)	5/6 (83.3%)
Prevalence, range	2.2–50.0%	0.8–45.8%	0.8–10.8%	0.8–10.8%

Values included for congenital toxoplasmosis were those for infants